AndhraNews.net
Home » Features » Companies » Elan Corporation

Elan Corporation


Elan Corporation in News

Horizon Pharma plc Announces Board of Directors Following Closing of Acquisition of Vidara Therapeutics International plc
Horizon Pharma plc (NASDAQ: HZNP) today announced the appointment of its Board of Directors. The appointment of the Horizon Pharma plc Board follows the closing of the acquisition of Vidara Therapeutics International plc by Horizon Pharma, Inc. and the resulting parent entity being incorporated in Ireland under the name Horizon Pharma plc.

Theravance Reports 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the fourth quarter and full year ended December 31, 2013. Revenue for the fourth quarter and full year of 2013 was $1.6 million and $4.8 million, respectively. Net loss for the fourth quarter and full year of 2013 was $49.9 million and $170.7 million, respectively. Net loss per basic and diluted share was $0

Theravance Reports Third Quarter 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended September 30, 2013. Revenue for the third quarter of 2013 was $0.4 million. Net loss for the third quarter of 2013 was $47.0 million or $0.44 per diluted share. Cash and cash equivalents, short-term investments and marketable securities totaled $594.5 million as of September 30, 2013.

Tax Headache? Take Two Aspirin and Buy an Irish Biotech for $8.6 Billion, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- After fending off a series of hostile takeover attempts, Irish biotech company Elan Corporation (NYSE:ELN) (Dublin, Ireland) accepted the Perrigo Company's (NASDAQ:PRGO) (Allegan, Michigan) $8.6 billion offer. By becoming an "Irish" company, over-the-counter (OTC) king Perrigo could slash its tax liabilities in half.

Theravance Reports Second Quarter 2013 Financial Results
Theravance, Inc. (NASDAQ: THRX) (the "Company") reported today its financial results for the quarter ended June 30, 2013. Revenue for the second quarter of 2013 was $1.3 million. Net loss for the second quarter of 2013 was $36.4 million or $0.37 per diluted share. Cash and cash equivalents, short-term investments and marketable securities totaled $533.3 million as of June 30, 2013.

Elan Shareholders Do Not Approve Theravance/Elan Royalty Participation Transaction
Theravance, Inc. (NASDAQ: THRX) ("Theravance") today announced that shareholders of Elan Corporation, plc ("Elan") did not approve the Theravance/Elan royalty participation transaction proposal at Elan's Extraordinary General Meeting held in Dublin, Ireland.

Theravance and Elan Enter Into a $1.0 Billion Royalty Participation Agreement
Theravance, Inc

Covidien Announces Nominees to Board of Directors for Mallinckrodt Pharmaceutical Business
Covidien (NYSE:COV) announced nominees to the future board of directors of Mallinckrodt plc as Mallinckrodt prepares to become a separate, independently traded company in mid-2013

Equity Briefing: Healthcare Review Sees Centene, Cynosure & XenoPort Among Notable Gainers At Mid Day
The U.S. market slumped on Tuesday as concerns over Spain and Greece weighed on the market and a round of disappointing profit outlooks highlighted the effect of the euro zone debt crisis on corporate earnings. However, there are several healthcare stocks which are making hot moves at mid day on Tuesday.Centene Corp (NYSE:CNC) shares rose 6

Where Opportunity Is Found - Research & Analysis on SunTrust Banks, Inc. and Coventry Health Care, Inc.
This morning, www.MarketFoundations.com announced new reports highlighting SunTrust Banks, Inc. (NYSE: STI) and Coventry Health Care, Inc. (NYSE: CVH). Free research downloads are available at www.MarketFoundations.com/index.php?coa=STI&cob=CVH.

Equities Lead Investor Sentiment - Research Report on Nucor Corporation and Informatica Corporation
Today, www.EquityLeader.com introduced research coverage of Nucor Corporation (NYSE: NUE) and Informatica Corporation (NASDAQ: INFA). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=NUE&sm2=INFA.

A Forward Look, the Year Ahead - Featured Research on Crosstex Energy, Inc. and CVR Energy, Inc.
Today, www.BollingerReport.com introduced featured coverage of Crosstex Energy, Inc. (NASDAQ: XTXI) and CVR Energy, Inc. (NYSE: CVI). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=XTXI&sm2=CVI.

Brower Piven Encourages Investors Who Have Losses in Excess of $1,000,000 From Investment in The Bank of New York Mellon Corporation to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the February 13, 2012 Lead Plaintiff Deadline

Enhance or Disrupt? Report on Healthcare Reform -- Equity Research on Elan Corporation and Biogen Idec Inc.
Today, www.EquityMarketsInc.com announced its research report highlighting Elan Corporation (NYSE: ELN) and Biogen Idec Inc. (NASDAQ: BIIB). Full content and research is available at www.EquityMarketsInc.com/research.php.

Comment on this story

Share